Immune response induced by recombinant BCG expressing merozoite surface antigen 2 from Plasmodium falciparum

Vaccine

Volumn 20, Issue 5-6, 2001, Pages 914-919

  Zheng, Chunfu ^a   Xie, Peimei ^b   Chen, Yatang ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Fujian Provincial Maternity and Child Health Hospital   (China)

Author keywords

Merozoite surface antigen 2; Plasmodium falciparum; Recombinant BCG

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; INTERLEUKIN 12; LIVE VACCINE; MEROZOITE SURFACE PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BCG VACCINATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; TREATMENT OUTCOME; TUBERCULOSIS; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BCG VACCINE; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; VACCINES, SYNTHETIC;

EID: 0035852326     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00382-6     Document Type: Article

References (31)

1. Expression of foreign genes in mycobacteria
2. New use of BCG for recombinant vaccines
3. Beyond BCG: Developing recombinant BCG multivaccine vehicle
4. The genetic reconstruction of BCG as a new immunotherapeutic fool
5. World malaria situation in 1994
6. Progress toward malaria pre-erythrocytic vaccines
7. An amount of 46-53 kDa glycoprotein from the surface of P. falciparum merozoites
8. Polymorphism of a 35-48 kDa P. falciparum merozoite surface antigen
9. Studies on glycoproteins in the human malaria parasite P. falciparum. Identification of a myristilated 45 kDa merozoite membrane glycoprotein
10. Identification of two integral membrane proteins of P. falciparum
11. Sequence comparison of allelic forms of the P. falciparum merozoite surface antigen MSA2
12. Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3
13. Protective immunization with invariant peptides of the P. falciparum antigen MSA2
14. Safety, immunogenicity, and pilot efficacy of P. falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults
15. Human phase I vaccine trials of three recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant
16. Introduction of foreign DNA into mycobacteria using a shuttle phasmid
17. Gene replacement and expression of foreign DNA in mycobacteria
18. New use of BCG for recombinant vaccines
19. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines
20. Expression of heterologous genes in M. bovis-BCG: Induction of a cellular response against HIV-1 Nef protein
21. Construction of shuttle expression plasmid and stable expression of foreign gene in mycobacteria and E. coli
22. Expression of foreign gene in mycobacterium regulated by human M. tuberculosis heat shock protein 70 promoter
23. Introduction of foreign DNA into mycobacteria using a shuttle phasmid
24. New use of BCG for recombinant vaccines
25. Structural diversity in the 45 kDa merozoite surface antigen of P. falciparum
26. Amino acid sequences recognized by T cells: Studies on a merozoite surface antigen from the FCQ-27/PNG isolate of P. falciparum
27. Relationship between humoral response to merozoite surface antigen 2 and malaria morbidity in highly endemic area of PNG
28. An epitope recognized by inhibitory monoclonal antibodies that react with a 51 kDa merozoite surface antigen in P. falciparum
29. Assessment of the role of the humoral response to P. falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria